首页> 外文期刊>Molecular medicine reports >Additive effects of eukaryotic co-expression plasmid carrying GRIM-19 and LKB1 genes on breast cancer in vitro and in vivo
【24h】

Additive effects of eukaryotic co-expression plasmid carrying GRIM-19 and LKB1 genes on breast cancer in vitro and in vivo

机译:携带GRIM-19和LKB1基因的真核共表达质粒在体内外对乳腺癌的加性作用

获取原文
获取原文并翻译 | 示例
           

摘要

Gene associated with retinoid-interferon-induced mortality 19 (GRIM-19) and the liver kinase B1 (LKB1) gene, two types of tumor suppressor gene, have been demonstrated to have important roles in breast carcinogenesis. The present study developed a dual expression plasmid that co-expressed GRIM-19 and LKB1, and evaluated the combined effects of the two genes against breast cancer in vitro and in vivo. Transfection with a plasmid for the simultaneous expression of GRIM-19 and LKB1 (pGRIM19-LKB1) into MCF-7 breast cancer cells significantly inhibited the proliferation, colony formation, migration and invasion compared with the effects of transfection with either pGRIM-19 or pLKB1 alone. Furthermore, transfection with pGRIM19-LKB1 induced enhanced levels of apoptosis and cell cycle arrest at G0/G1 stage in MCF7 cells compared to the effects of pGRIM-19 or pLKB1 alone. An in vivo experiment using an MCF-7 xenograft tumor model demonstrated that intravenous injection of pGRIM19-LKB1 had an enhanced effect on tumor growth inhibition compared to that of pGRIM-19 or pLKB1 alone. In conclusion the findings of the present study suggested that transfection with eukaryotic plasmid for the simultaneous expression of GRIM-19 and LKB1 more effectively suppressed the growth of breast cancer in vitro and in vivo, and may therefore have therapeutic potential for the treatment of human breast cancer.
机译:已经证明与类维生素A-干扰素诱导的死亡相关的基因19(GRIM-19)和肝激酶B1(LKB1)基因是两种类型的肿瘤抑制基因,在乳癌的发生中具有重要作用。本研究开发了一种共表达GRIM-19和LKB1的双重表达质粒,并评估了这两个基因在体外和体内对乳腺癌的联合作用。与同时转染pGRIM-19或pLKB1的效果相比,用质粒转染GRIM-19和LKB1(pGRIM19-LKB1)同时表达到MCF-7乳腺癌细胞中,可显着抑制增殖,集落形成,迁移和侵袭。单独。此外,与pGRIM-19或pLKB1单独作用相比,pGRIM19-LKB1转染诱导MCF7细胞在G0 / G1阶段凋亡水平提高,细胞周期停滞。使用MCF-7异种移植肿瘤模型的体内实验表明,与单独使用pGRIM-19或pLKB1相比,静脉注射pGRIM19-LKB1对肿瘤生长的抑制作用增强。总之,本研究的结果表明,用真核质粒转染同时表达GRIM-19和LKB1可以更有效地抑制体内外乳腺癌的生长,因此可能具有治疗人类乳腺癌的潜力。癌症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号